10,583 Shares in Actuate Therapeutics (NASDAQ:ACTU) Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics (NASDAQ:ACTU) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,583 shares of the company’s stock, valued at approximately $84,000.

Several other large investors also recently added to or reduced their stakes in ACTU. Freestone Capital Holdings LLC purchased a new stake in Actuate Therapeutics in the 4th quarter worth about $80,000. Envestnet Asset Management Inc. purchased a new stake in Actuate Therapeutics in the 4th quarter worth about $83,000. Sigma Planning Corp purchased a new stake in Actuate Therapeutics in the 4th quarter worth about $128,000. Mercer Global Advisors Inc. ADV purchased a new stake in Actuate Therapeutics in the 4th quarter worth about $130,000. Finally, Voss Capital LP purchased a new stake in Actuate Therapeutics in the 4th quarter worth about $440,000.

Actuate Therapeutics Stock Up 3.3%

ACTU stock opened at $10.60 on Wednesday. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73. The stock has a 50-day simple moving average of $8.34 and a two-hundred day simple moving average of $8.31.

Actuate Therapeutics (NASDAQ:ACTU) last posted its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06).

Analyst Ratings Changes

Several brokerages recently weighed in on ACTU. HC Wainwright started coverage on Actuate Therapeutics in a report on Monday, March 17th. They issued a “buy” rating and a $20.00 price objective for the company. Craig Hallum started coverage on Actuate Therapeutics in a report on Tuesday, April 22nd. They set a “buy” rating and a $21.00 target price for the company.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.